Cyclopharm Limited delivered a record $17.1 million in revenue for 1H FY26, driven by a 73% surge in US Technegas® sales. However, delays in clinical guideline publication have pushed the short-term US installation target beyond 2026, while medium-term ambitions remain intact.
- 1H FY26 revenue up 11% to $17.1 million
- US Technegas® revenue surges 73% year-on-year
- US installations reach 70 sites, pipeline exceeds 1,650 locations
- International lung scintigraphy guidelines approved but publication delayed
- Cash position strengthens to $12.2 million, peak cash burn passed
Record Revenue Highlights US Growth Momentum
Cyclopharm Limited (ASX:CYC) has reported a record first half of FY26, with global revenues hitting approximately $17.1 million, marking an 11% increase over the prior corresponding period. The standout contributor was the United States, where Technegas® revenue soared by around 73% to $2.1 million, reflecting the rapid expansion of revenue-generating installations now at 70 primary sites as of 1 July 2026. This growth underscores the US market’s emergence as Cyclopharm’s primary near-term revenue engine.
US Installation Target Deferred Amid Guideline Publication Delay
Despite this momentum, Cyclopharm has deferred its short-term guidance of reaching 250–300 revenue-generating US locations to after 31 December 2026. The delay stems from a protracted, multi-society approval process for revised international lung scintigraphy clinical guidelines, which now include the US, Europe, and ANZ markets. These guidelines, which explicitly designate Technegas® as the preferred ventilation imaging agent and expand clinical indications beyond pulmonary embolism, have received final approval and are awaiting publication by the US Journal of Nuclear Medicine. The timing of this publication remains outside Cyclopharm’s control but is expected to catalyse further adoption once released.
Management remains confident in achieving its medium-term US target of over 2,000 revenue-generating installations, supported by a pipeline of more than 1,650 engaged locations and 331 contracted sites. Notably, several high-profile academic, federal, and major health-system facilities, such as the National Institutes of Health, Walter Reed National Military Medical Center, and Northwestern Memorial Hospital, have become revenue-generating sites, enhancing Cyclopharm’s clinical credibility and network expansion potential.
Recurring Revenue Model Strengthens Cash Flow Outlook
The company’s commercial model centres on recurring consumable revenues that compound with each new installation and affiliated network expansion. With 70 primary US sites linked to 429 affiliated locations, Cyclopharm is building a durable annuity revenue base. This dynamic has driven a reduction in net cash consumption, with the company reporting a closing cash balance of approximately $12.2 million as of 30 June 2026, up from $6.6 million at the end of December 2025. Management believes peak cash burn has passed, anticipating that growing recurring revenues will progressively reduce cash outflows.
AI Integration Expands Clinical Applications Beyond Pulmonary Embolism
Technegas®’s unique ability to provide real-time functional lung imaging at a radiation dose significantly lower than CT pulmonary angiography is being leveraged in AI-driven diagnostic tools. These collaborations aim to extend Technegas®’s clinical utility beyond pulmonary embolism to conditions such as COPD, asthma, lung cancer, and pulmonary hypertension, all under the existing broad USFDA approval. This convergence of functional imaging and AI is central to Cyclopharm’s Beyond PE strategy, potentially unlocking a US market opportunity estimated at up to US$900 million, atop the current US$180 million pulmonary embolism market.
Commercial Infrastructure and Clinical Validation Align for Growth
CEO James McBrayer highlighted that the company’s commercial infrastructure is now in place and that the clinical community supports Technegas®. The upcoming publication of the revised international guidelines is expected to reinforce Technegas®’s positioning and accelerate adoption. Cyclopharm’s commitment to quarterly pipeline reporting offers shareholders granular visibility into contract execution, installation progress, and revenue generation, providing a transparent view of the company’s trajectory as it scales its US footprint.
Bottom Line?
Cyclopharm’s record half-year performance confirms the US as a growth engine, but delayed guideline publication tempers near-term installation targets, making the timing of market adoption the key watchpoint.
Questions in the middle?
- When will the revised international lung scintigraphy guidelines be published, and how quickly will this influence US installations?
- How will AI-driven clinical applications translate into tangible revenue growth beyond pulmonary embolism?
- What is the conversion rate from the large engaged pipeline of over 1,650 US locations into revenue-generating sites in the medium term?